Abstract:Background: Small interfering RNA (siRNA) is utilized as a potent agent for cancer therapy through regulating the expression of genes associated with tumors. While the widely application of siRNAs in cancer treatment is severely limited by their insufficient biological stability and its poor ability to penetrate cell membranes. Targeted delivery systems hold great promise to selectively deliver loaded drug to tumor site and reduce toxic side effect. However, the elevated tumor interstitial fluid pressure and efficient cytoplasmic release are still two significant obstacles to siRNA delivery. Co-delivery of chemotherapeutic drugs and siRNA represents a potential strategy which may achieve synergistic anticancer effect. Herein, we designed and synthesized a dual pH-responsive peptide (DPRP), which includes three units, a cell-penetrating domain (polyarginine), a polyanionic shielding domain (ehG)n, and an imine linkage between them. Based on the DPRP surface modification, we developed a pH-responsive liposomal system for co-delivering polo-like kinase-1 (PLK-1) specific siRNA and anticancer agent docetaxel (DTX), D-Lsi/DTX, to synergistically exhibit anti-tumor effect. Results: In contrast to the results at the physiological pH (7.4), D-Lsi/DTX lead to the enhanced penetration into tumor spheroid, the facilitated cellular uptake, the promoted escape from endosomes/lysosomes, the improved distribution into cytoplasm, and the increased cellular apoptosis under mildly acidic condition (pH 6.5). Moreover, both in vitro and in vivo study indicated that D-Lsi/DTX had a therapeutic advantage over other control liposomes. We provided clear evidence that liposomal system co-delivering siPLK-1 and DTX could significantly downregulate expression of PLK-1 and inhibit tumor growth without detectable toxic side effect, compared with siPLK-1-loaded liposomes, DTX-loaded liposomes, and the combinatorial administration. Conclusion: These results demonstrate great potential of the combined chemo/gene therapy based on the multistage pH-responsive codelivery liposomal platform for synergistic tumor treatment.

A tumor-activatable peptide supramolecular nanoplatform for the delivery of dual-gene targeted siRNAs for drug-resistant cancer treatment

Biocompatible, Chimeric Peptide-Condensed Supramolecular Nanoparticles for Tumor Cell-Specific Sirna Delivery and Gene Silencing.

Nanoparticles co-delivering siRNA and mRNA for simultaneous restoration and silencing of gene/protein expression in vitro and in vivo

A Dual-Locked Cyclopeptide-Sirna Conjugate for Tumor-Specific Gene Silencing.

The Ph-Triggered Triblock Nanocarrier Enabled Highly Efficient Sirna Delivery for Cancer Therapy

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy

Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance

Smart Nanoparticles Assembled by Endogenous Molecules for Sirna Delivery and Cancer Therapy Via CD44 and EGFR Dual-Targeting

A Supramolecular Co-Delivery Strategy for Combined Breast Cancer Treatment and Metastasis Prevention

Efficient nanocarriers of siRNA therapeutics for cancer treatment

Long double-stranded multiplex siRNAs for dual genes silencing.

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery

Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment

Ph-Responsive Complexes Using Prefunctionalized Polymers for Synchronous Delivery of Doxorubicin and Sirna to Cancer Cells

Enhancing Sirna-Based Cancer Therapy Using a New Ph-Responsive Activatable Cell-Penetrating Peptide-Modified Liposomal System

A Nanoplatform Self-Assembled by Coordination Delivers Sirna for Lung Cancer Therapy

Tumor-targeted Delivery of Sirna by Surface-Modified LPC Nanoparticles

Tumor microenvironment responsive nano-herb and CRISPR delivery system for synergistic chemotherapy and immunotherapy

T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.